Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Completed · Phase 1/Phase 2

Conditions studied: Colorectal Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive to chemotherapy drugs. Combining irinotecan and oblimersen may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining oblimersen and irinotecan in treating patients who have metastatic or recurrent colorectal cancer.

Key facts

Study ID

NCT00004870

Run by

The University of Texas Health Science Center at San Antonio

Starts

2000-06-01

Expected to finish

2002-09-01

Last updated by the study team

2013-02-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Ireland Cancer Center — Cleveland, Ohio, United States
• Brooke Army Medical Center — Fort Sam Houston, Texas, United States
• San Antonio Cancer Institute — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.